Trial · NCT04628338
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
NCT04628338, Early phase 1, Completed, Sawa Ito, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation. Trials, record NCT04628338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04628338
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
- NCT number
- NCT04628338
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 8 participants, actual
- Lead sponsor
- Sawa Ito, MD
- Conditions
- Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
- Interventions
- IFN-γ (interferon gamma-1b) injection
- First posted
- 2020-11-13
- Last updated
- 2025-04-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Upregulation HLA l (HLA-ABC) | Up to 6 months | Upregulation of HLA l (HLA-ABC) in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry. |
| Primary | Upregulation of HLA ll (HLA-DR/DQ) | Up to 6 months | Upregulation of HLA ll (HLA-DR/DQ) in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry. |
| Primary | Upregulation of ICAM-1 | Up to 6 months | Upregulation of ICAM-1 in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells. |
| Primary | Adverse events related to IFN-γ | Up to 6 months | Adverse events of IFN-γ in relapsed patients after alloSCT per CTCAE v5.0. |
| Primary | Generation of phosphorylated-STAT1 | Up to 6 months | Generation of phosphorylated-STAT1 in bone marrow malignant blasts post-IFN-γ treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells. |
| Secondary | Malignant Blast Burden | Up to 6 months | Change in malignant blasts number after IFN-γ therapy and subsequent donor lymphocyte infusion. |
| Secondary | Incidence of GVHD | Up to 6 months | Incidence of Graft Versus Host Disease (GVHD) progression or de novo GVHD after INF-g therapy and subsequent donor lymphocyte infusion. |
| Secondary | Incidence of de novo GVHD | Up to 6 months | Incidence of graft-versus-host disease (GVHD) progression after IFN-γ therapy and subsequent DLI. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40131369 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04628338
GET https://conductscience.org/api/trials/v1/NCT04628338/registered